SynthesisEuropean journal of clinical pharmacology2025

Imeglimin systematic review: a novel therapeutic approach for type 2 diabetes-unveiling benefits on β-cell function, insulin sensitivity, and potential long-term glycaemic control (HbA1c).

S Murshidha Shireen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.